Journal of Pharmacovigilance

Importance of Patient Reporting in Pharmacovigilance and Drug Safety

Dritan Agalliu^* Department of Pharmacy, Monmouth Medical Center, New Jersey, USA
^*Correspondence: Dritan Agalliu, Department of Pharmacy, Monmouth Medical Center, New Jersey, USA, Email:

Received: 01-Jan-2023, Manuscript No. JP-22-20159; Editor assigned: 03-Jan-2023, Pre QC No. JP-22-20159(PQ); Reviewed: 17-Jan-2023, QC No. JP-22-20159; Revised: 24-Jan-2023, Manuscript No. JP-22-20159(R); Published: 31-Jan-2023, DOI: 10.35248/2329-6887.23.11.416

About the Study

Pharmacovigilance is a vital component of modern medicine, and it refers to the process of monitoring, evaluating, and reporting Adverse Drug Reactions (ADRs) and other drug-related problems. The primary goal of pharmacovigilance is to ensure that patients receive safe and effective medications while minimizing the risks associated with drug use. This article will explore the role of pharmacovigilance in ensuring drug safety and the significance of this practice in modern healthcare.

Importance of pharmacovigilance in ensuring drug safety

Pharmacovigilance is essential in ensuring drug safety for several reasons. First, it helps to identify new or unexpected ADRs that may not have been detected during clinical trials. This is important because clinical trials are conducted on a limited number of patients and may not fully reflect the diversity of the patient population. As a result, rare or severe ADRs may not be discovered until after the drug has been approved and is being used by a larger population [1,2].

Second, pharmacovigilance helps to identify drug interactions, which can lead to adverse reactions that were not predicted during clinical trials. Drug interactions occur when two or more medications are taken together and interact with each other, resulting in an increased risk of side effects or a decrease in the effectiveness of one or both drugs. Pharmacovigilance helps to identify drug interactions and provides guidance on how to manage them.

Third, pharmacovigilance plays a critical role in post-marketing surveillance, where the safety and efficacy of drugs are monitored after they have been approved for use. This monitoring helps to identify any new risks associated with the drug and evaluate its long-term safety and efficacy [3,4].

Role of pharmacovigilance in ensuring drug safety

Pharmacovigilance plays a vital role in ensuring drug safety by:

Collecting and analyzing adverse drug reaction reports: Pharmacovigilance systems collect reports of ADRs from healthcare professionals and patients. These reports are analyzed to identify patterns and trends in adverse reactions and to evaluate their severity and impact on patient health.

Identifying and evaluating drug interactions: Pharmacovigilance systems monitor drug interactions and evaluate their impact on patient health. This information is used to provide guidance on how to manage drug interactions and to prevent adverse reactions [5,6].

Providing guidance on medication errors: Pharmacovigilance systems provide guidance on how to prevent medication errors and how to manage them when they occur. This information is used to improve medication safety and prevent adverse reactions.

Conducting post-marketing surveillance: Pharmacovigilance systems monitor the safety and efficacy of drugs after they have been approved for use. This monitoring helps to identify any new risks associated with the drug and to evaluate its long-term safety and efficacy [7,8].

Communicating drug safety information: Pharmacovigilance systems communicate drug safety information to healthcare professionals and patients. This information helps to improve patient safety and prevent adverse reactions.

Importance of collaboration in pharmacovigilance

Pharmacovigilance requires collaboration among healthcare professionals, regulatory authorities, pharmaceutical companies, and patients. Collaboration is essential in ensuring that ADRs are identified and managed effectively.

Healthcare professionals play a critical role in reporting ADRs and providing information on medication errors. They also play a key role in educating patients about the risks associated with medications and how to manage adverse reactions [9,10].

Regulatory authorities are responsible for approving drugs for use and monitoring their safety and efficacy. They work closely with pharmaceutical companies to ensure that drugs are safe and effective before they are approved for use.

Pharmaceutical companies are responsible for conducting clinical trials and providing information on the safety and efficacy of drugs. They also play a critical role in monitoring the safety of drugs after they have been approved for use.

References

1. Terzano C, Conti V, Di Stefano F, Petroianni A, Ceccarelli D, Graziani E, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188:321-329.

   [Crossref] [Google Scholar] [PubMed]

2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341-1351.

   [Crossref] [Google Scholar] [PubMed]

3. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31(1):58-69.

   [Crossref] [Google Scholar] [PubMed]

4. Cheng JS, Huang WF, Lin KM, Shih YT. Characteristics associated with benzodiazepine usage in elderly outpatients in Taiwan. Int J Geriatr Psychiatry. 2008;23(6):618-624.

   [Crossref] [Google Scholar] [PubMed]

5. Light RW, Merrill EJ, Despars JA, Gordon GH, Mutalipassi LR. Prevalence of depression and anxiety in patients with COPD: relationship to functional capacity. Chest. 1985;87(1):35-38.

   [Crossref] [Google Scholar] [PubMed]

6. Kontopoulou K, Iosifidis E, Antoniadou E, Tasioudis P, Petinaki E, Malli E, et al. The clinical significance of carbapenem-resistant Klebsiella pneumoniae rectal colonization in critically ill patients: from colonization to bloodstream infection. J Med Microb. 2019; 68(3):326-35.

   [Crossref] [Google Scholar] [PubMed]

7. Li Y, Shen H, Zhu C, Yu Y. Carbapenem-resistant Klebsiella pneumoniae infections among ICU admission patients in central China: Prevalence and prediction model. BioMed Res Int. 2019; 9767313.

   [Crossref] [Google Scholar] [PubMed]

8. Forde C, Stierman B, Ramon-Pardo P, Dos Santos T, Singh N. Carbapenem-resistant Klebsiella pneumoniae in barbados: driving change in practice at the national level. PLoS One. 2017; 12(5):e0176779.

   [Crossref] [Google Scholar] [PubMed]

9. Marsh JW, Mustapha MM, Griffith MP, Evans DR, Ezeonwuka C, Pasculle AW, et al. Evolution of outbreak-causing carbapenem-resistant Klebsiella pneumoniae ST258 at a tertiary care hospital over 8 years. MBio. 2019; 10(5):e01945-1919.

   [Crossref] [Google Scholar] [PubMed]

10. Humphries RM, Yang S, Kim S, Muthusamy VR, Russell D, Trout AM, et al. Duodenoscope-related outbreak of a carbapenem-resistant klebsiella pneumoniae identified using advanced molecular diagnostics. Clin Infect Dis. 2017; 65(7):1159-1166.

    [Crossref] [Google Scholar] [PubMed]